109 related articles for article (PubMed ID: 17611572)
21. [Primary hemorrhagic thrombocythemia. 3 cases].
Torre-Lopez E; Sanchez-Medal L
Sangre (Barc); 1971; 16(3):305-13. PubMed ID: 5287077
[No Abstract] [Full Text] [Related]
22. Conditioning regimens including high-dose busulfan cause a high incidence of transplant-related mortality after myeloablative stem cell transplantation.
Nakamae H; Yamane T; Aoyama Y; Yamamura R; Ohta K; Hino M
Chemotherapy; 2004 Oct; 50(4):178-83. PubMed ID: 15347910
[TBL] [Abstract][Full Text] [Related]
23. [Essential thrombocythemia. Apropos of 3 cases].
Sanz Marca A; Rico Pérez MT; Aboín Massieu FJ; Rebollar Mesa JL
Rev Clin Esp; 1983 Mar; 168(5):347-50. PubMed ID: 6683423
[No Abstract] [Full Text] [Related]
24. Essential thrombocythemia: a relative benign long-term course.
Meisel S; Shpilberg O; Ramot B; Ben-Bassat I
Isr J Med Sci; 1993 Apr; 29(4):190-4. PubMed ID: 8491569
[TBL] [Abstract][Full Text] [Related]
25. [Clinical conference: Thrombocythemic introduction to chronic myeloid leukemia].
Bauters F; Goudemand M
Nouv Rev Fr Hematol; 1975; 15(2):241-4. PubMed ID: 126433
[No Abstract] [Full Text] [Related]
26. Bone marrow aplasia after pipobroman: an immune-mediated mechanism?
Triffet A; Straetmans N; Ferrant A
Br J Haematol; 2001 Dec; 115(3):713-4. PubMed ID: 11736962
[No Abstract] [Full Text] [Related]
27. [Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia].
Kubota Y; Waki M
Rinsho Ketsueki; 2009 Mar; 50(3):197-202. PubMed ID: 19352088
[TBL] [Abstract][Full Text] [Related]
28. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
[TBL] [Abstract][Full Text] [Related]
29. Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
Heli U; Eeva J; Anne N; Tapani R; Liisa V
Eur J Haematol; 2012 Jan; 88(1):87-8. PubMed ID: 22103782
[No Abstract] [Full Text] [Related]
30. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
31. Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia.
Corker E; Astwood E; Williams J; Vora A
Br J Haematol; 2012 Oct; 159(1):104-6. PubMed ID: 22804487
[No Abstract] [Full Text] [Related]
32. Primary or hemorrhagic thrombocythemia.
Silverstein MN
Arch Intern Med; 1968 Jul; 122(1):18-22. PubMed ID: 5301705
[No Abstract] [Full Text] [Related]
33. [Diagnosis and treatment of essential thrombocythemia].
Kuramoto A
Rinsho Ketsueki; 1995 May; 36(5):480-6. PubMed ID: 7783354
[TBL] [Abstract][Full Text] [Related]
34. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.
Greystoke B; Bonanomi S; Carr TF; Gharib M; Khalid T; Coussons M; Jagani M; Naik P; Rao K; Goulden N; Amrolia P; Wynn RF; Veys PA
Br J Haematol; 2008 Jun; 142(2):257-62. PubMed ID: 18492115
[TBL] [Abstract][Full Text] [Related]
35. [Long-term treatment of thrombocytosis and thrombocythemia].
Linker H; Lindner HJ; Reuter H; Gross R
Med Welt; 1980 Apr; 31(14):509-12. PubMed ID: 7189572
[No Abstract] [Full Text] [Related]
36. Herb-drug interactions.
Windrum P; Hull DR; Morris TC
Lancet; 2000 Mar; 355(9208):1019-20. PubMed ID: 10768466
[No Abstract] [Full Text] [Related]
37. [Therapy of blast crises in megakaryocytic myelosis].
Zurborn KH; Bruhn HD; Feller A
Dtsch Med Wochenschr; 1984 Apr; 109(14):556-7. PubMed ID: 6538475
[No Abstract] [Full Text] [Related]
38. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
39. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
40. [Some questions on the problem of thrombocythemia].
Frinovskaia IV
Probl Gematol Pereliv Krovi; 1968 Nov; 13(11):7-13. PubMed ID: 5753808
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
